Sophia Umansky—the daughter of Kyle Richards and Mauricio Umansky—doubled down on her decision to take Mounjaro, despite ...

The administration might be launching a campaign specifically targeting such products. This would follow Monday's executive ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Novo Nordisk now forecasts 2025 sales growth between ... Eli Lilly. Demand for GLP-1 weight-loss drugs surged throughout 2024, significantly outpacing supply. Under US Food and Drug Administration ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...